Testing ALKS 2680 for adults with narcolepsy type 1
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of narcolepsy type 1 (based on a sleep study or low hypocretin levels in spinal fluid).
- You do not have any other sleep disorders that could affect your sleep-wake cycle.
- You do not have any other serious medical conditions that could make the study unsafe or interfere with results.
- You are not currently in another clinical trial and have not taken an investigational drug in the last 30 days.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with narcolepsy or idiopathic hypersomnia who have already taken part in an earlier ALKS 2680 study. It aims to see how well the medication works and how safe it is when taken for a longer time.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
Hear when a new Narcolepsy Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.